GlassScriptPhysician profile
Adrienne Harris
NPI 1083318687
$4,520.52
in general payments reported to CMS, 2019-2025
31 companies · $1,596 in 2025
The $1,596 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $874 · 2024: $2,051 · 2025: $1,596.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,436 · Gift: $42.50 · Education: $42.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,435.52 |
| Gift | $42.50 |
| Education | $42.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $783.99 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $576.21 | 2023-2025 | Evenity, Tepezza, Prolia |
| Lilly USA, LLC | $566.18 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Dexcom, INC. | $446.03 | 2023-2025 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $285.40 | 2023-2025 | Recorlev, Gvoke Hypopen |
| Alexion Pharmaceuticals, INC. | $165.38 | 2023-2025 | Strensiq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $163.39 | 2023-2025 | Jardiance |
| Corcept Therapeutics | $154.38 | 2023-2025 | Korlym |
| Bayer Healthcare Pharmaceuticals INC. | $137.97 | 2023-2025 | |
| Antares Pharma, INC. | $129.35 | 2023-2025 | Xyosted, Tlando, Nocdurna |
| Sanofi-Aventis U.S. LLC | $127.02 | 2023-2025 | |
| Mannkind Corporation | $100.51 | 2024-2025 | |
| Recordati_rare_diseases_inc. | $96.64 | 2024-2025 | Isturisa, Signifor Lar |
| Merck Sharp & Dohme LLC | $94.63 | 2024 | Dificid, Pifeltro, Delstrigo |
| Beta Bionics, INC. | $88.45 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ascensia Diabetes Care US INC. | $80.99 | 2024-2025 | |
| Amneal Pharmaceuticals LLC | $73.60 | 2023-2025 | Unithroid |
| Ibsa Pharma INC. | $61.61 | 2023-2025 | Tirosint, Flector, Licart |
| Tandem Diabetes Care, INC. | $59.23 | 2023-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Pfizer INC. | $55.32 | 2023-2025 | |
| Radius Health, INC. | $51.52 | 2025 | |
| Esperion Therapeutics, INC. | $33.10 | 2023 | Nexletol |
| Neurocrine Biosciences, INC. | $28.17 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $23.99 | 2025 | Evkeeza |
| Theratechnologies INC. | $23.33 | 2024 | Trogarzo, Egrifta |
| Abbvie INC. | $21.80 | 2024 | |
| Insulet Corporation | $21.42 | 2024 | Omnipod |
| Melinta Therapeutics, LLC | $20.26 | 2024 | Rezzayo, Vabomere, Orbactiv |
| Halozyme INC | $18.09 | 2023 | |
| Sequel Med Tech, LLC | $17.88 | 2025 | Twiist |
| Amphastar Pharmaceuticals, INC. | $14.68 | 2024 | Baqsimi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adrienne Harris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.